Safety and Tolerability of Glyceryl Tribenzoate (GTB) Capsules in Healthy Subjects
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05938452 |
Recruitment Status :
Completed
First Posted : July 10, 2023
Last Update Posted : January 11, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Neurological Disorder | Drug: Glyceryl Tribenzoate | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 40 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Phase 1, Randomized, Double-Blind, Single-Dose Escalation Study Followed by a Multiple-Dose Escalating Study of Glyceryl Tribenzoate (GTB) Capsules in Healthy Subjects |
Actual Study Start Date : | December 12, 2022 |
Actual Primary Completion Date : | October 19, 2023 |
Actual Study Completion Date : | October 19, 2023 |
Arm | Intervention/treatment |
---|---|
Experimental: Active
Active Comparator
|
Drug: Glyceryl Tribenzoate
Oral Solution |
Placebo Comparator: Placebo
Placebo Comparator
|
Drug: Glyceryl Tribenzoate
Oral Solution |
- Treatment-Emergent Adverse Events [ Time Frame: 7 days ]
Incidence of Treatment-Emergent Adverse Events (TEAEs) until 30 days after the last administration of the study medication.
6. Change from baseline in 12-lead electrocardiogram (ECG).
- Treatment-Emergent Adverse Events Withdrawals [ Time Frame: 7 days ]Incidence of TEAEs leading to withdrawal of study drug or study discontinuation.
- Laboratory Results [ Time Frame: 7 days ]Change from baseline in clinical laboratory results.
- Physical Results [ Time Frame: 7 days ]Change from baseline in physical examination results
- Vital Signs [ Time Frame: 7 days ]Change from baseline in vital signs.
- Electrocardiogram [ Time Frame: 7 days ]Change from baseline in 12-lead electrocardiogram (ECG).
![](/ct2/html/images/NIH_NLM_ABRV_BLK_4.png)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 50 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Signed informed consent prior to any study-related procedures.
- Male or female subjects 18 to 50 years of age inclusive.
- Subject's body mass index (BMI) is ≥ 18 kg/m2 and ≤ 30 kg/m2.
- Female subjects of childbearing potential must not be pregnant or lactating with a negative serum human chorionic gonadotropin (HCG) pregnancy test result at Screening, and negative urine pregnancy test on Day -1 (including Day -1 of Period 2 for SAD dosing participants i.e., fed cohort).
- Female subjects of childbearing potential must use an adequate method of contraception from Screening until 30 days after last dose of study medication. Acceptable methods of contraception are barrier methods (female condom, diaphragm, cervical cap, spermicide, or intrauterine device [IUD]), surgical sterility (self-reported: tubal ligation, hysterectomy, and/or bilateral oophorectomy), oral hormonal contraceptives, hormonal IUD, and/or postmenopausal status (defined as at least 1 year without menses as demonstrated by medical history or subject report).
- Male subjects must use an adequate method of contraception from Screening until 30 days after last dose of study medication. Acceptable methods of contraception are barrier methods (condom), surgical sterility (self-reported), must also refrain from donating sperm while on study medication and until 30 days after last dose of study medication.
- Subject is in good health as determined by vital signs, medical history, physical exam, ECG, and safety laboratory analyses at Screening and during the study.
- Subject is negative for SARS-CoV-2 virus at admission Day -1 and Day 1 (during the SAD, Fed portion of the study, and MAD).
- Subject does not have dysphagia and discomfort with swallowing tablets/capsules.
Exclusion Criteria:
- Subject has used an investigational product or device within 30 days prior to enrollment or during the study.
- Subject has used prescription or non-prescription drugs (including vitamins, minerals, and herbal/plant-derived preparations) within 2 weeks of enrollment (excluding hormonal IUD, oral hormonal contraceptives, hormone replacement therapy, and acetaminophen) unless deemed acceptable by the Investigator in consultation with the Sponsor.
- Subject has a positive drug and/or alcohol test at Screening and on Day -1 (including 4. Day -1 of Period 2 for SAD dosing participants, i.e., fed cohort).
- Subject has a history of drug or alcohol abuse within 2 years before Screening.
- Subject is unable to abstain from ingesting alcohol or smoking for 72 hours prior to dosing and throughout the study.
- Concurrent use of probenecid, penicillin or other ß-lactams, or other drugs which undergo active tubular secretion in the kidneys.
- The subject has a clinically significant history of endocrinologic, hematologic, hepatic, immunologic, metabolic, cardiovascular, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major diseases or malignancy.
- Allergy to sodium benzoate.
- Has an active suicidal plan/intent or have had active suicidal thoughts in the past 6 months or a suicide attempt in the past 3 years.
![](/ct2/html/images/NIH_NLM_ABRV_BLK_4.png)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05938452
United States, New Jersey | |
TKL Research | |
Bloomfield, New Jersey, United States, 07003 |
Responsible Party: | Forest Hills Lab |
ClinicalTrials.gov Identifier: | NCT05938452 |
Other Study ID Numbers: |
FHL-101-001 |
First Posted: | July 10, 2023 Key Record Dates |
Last Update Posted: | January 11, 2024 |
Last Verified: | June 2023 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Nervous System Diseases |